Trial Profile
A Prospective, Randomized, Double-Blind, Placebo Controlled Study of the Long-Term Efficacy of Nebivolol in Hypertensive Patients After Withdrawal of Therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2010
Price :
$35
*
At a glance
- Drugs Nebivolol (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- Sponsors Forest Laboratories
- 07 May 2010 Results presented at the 25th Annual Scientific Meeting of the American Society of Hypertension.
- 14 Apr 2010 Actual patient number (207) added as reported by ClinicalTrials.gov.
- 07 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.